30s Ad: $35 - $44
60s Ad: $42 - $50
CPM Category: Health & Fitness
Different podcast categories command different CPM (cost per mille) rates based on advertiser demand and audience value.
Socials metrics & links
Socials metrics & links
No data
No data
Podcast LinksLinks to the podcast's website, socials, and more
Learn from the brightest CEOs in medtech and healthtech. That's our primary goal with Medsider. We unpack the strategies, tactics, and secrets behind the most successful startups. Join tens of thousands of ambitious doers and get access to the top medical device and health technology thought leaders.
Learn from the brightest CEOs in medtech and healthtech. That's our primary goal with Medsider. We unpack the strategies, tactics, and secrets behind the most successful startups. Join tens of thousands of ambitious doers and get access to the top medical device and health technology thought leaders.
Producers, Hosts, and Production Team
Searching
Searching for producer information... This may take a moment.
No producer information available yet. Click "Find producers" to search for the production team.
Emails, Phones, and Addresses
Contact Page Emails
Emails listed specifically on the website's official contact page.
Emails
Phone Numbers
No phone numbers found.
Addresses
No addresses found.
Form
A contact form is available on this page.
You can fill out the form at
this link.
General Website Emails
Emails found on general website pages (e.g., about, info), not the main contact page.
No website emails found.
Externally Sourced Emails
Emails discovered using automated web scraping across the internet.
No external emails found.
RSS Emails
Email addresses extracted directly from the website's or podcast's RSS feed(s).
Here's a quick summary of the last 5 episodes on Medsider: Learn from Medtech and Healthtech Founders and CEOs.
Hosts
Medsider Radio
Previous Guests
Claire Dixon
Claire Dixon is the CEO and co-founder of Neuraura, a company focused on developing innovative solutions for women's health, particularly targeting PCOS through their product LoOop, an over-the-counter wearable device. With over 25 years of international leadership experience, Claire holds a master's degree in engineering from Cambridge and an MBA from Harvard. Before her entrepreneurial journey, she spent 15 years as a strategic consultant for capital-intensive businesses. Claire has been recognized as one of the Top 200 Trailblazing Leaders in Women's Health and femtech by Women of Wearables.
Claire Dixon is the CEO and co-founder of Neuraura, a company focused on developing innovative solutions for women's health, particularly targeting PCOS through their product LoOop, an over-the-counter wearable device. With over 25 years of international leadership experience, Claire holds a master's degree in engineering from Cambridge and an MBA from Harvard. Before her entrepreneurial journey, she spent 15 years as a strategic consultant for capital-intensive businesses. Claire has been recognized as one of the Top 200 Trailblazing Leaders in Women's Health and femtech by Women of Wearables.
Vicky Demas
Vicky Demas is the CEO of identifeye HEALTH, formerly known as Tesseract Health. She is leading efforts to democratize access to retinal imaging through advanced algorithms and automated systems that capture and analyze retinal images for early disease detection. Prior to her role at identifeye HEALTH, Vicky was instrumental in new product development at GRAIL, contributing to the creation of the multi-cancer early detection test, Galleri. She is also a founding member of Google Life Sciences (now Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An accomplished engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across various disciplines.
Vicky Demas is the CEO of identifeye HEALTH, formerly known as Tesseract Health. She is leading efforts to democratize access to retinal imaging through advanced algorithms and automated systems that capture and analyze retinal images for early disease detection. Prior to her role at identifeye HEALTH, Vicky was instrumental in new product development at GRAIL, contributing to the creation of the multi-cancer early detection test, Galleri. She is also a founding member of Google Life Sciences (now Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An accomplished engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across various disciplines.
Randy Pritchard
Randy Pritchard is the CEO of Axena Health, bringing nearly 25 years of healthcare experience to the company. He was most recently the CEO of Pillar Biosciences and has held leadership positions at Roche Diagnostics for 18 years, where he developed significant commercial expertise.
Randy Pritchard is the CEO of Axena Health, bringing nearly 25 years of healthcare experience to the company. He was most recently the CEO of Pillar Biosciences and has held leadership positions at Roche Diagnostics for 18 years, where he developed significant commercial expertise.
Erica Rogers
Erica Rogers is a leader at Axena Health, serving on its Board of Directors. She previously spent a decade as President and CEO of Silk Road Medical, guiding the company from early clinical trials through its IPO and eventual acquisition by Boston Scientific. Erica is a returning guest to the podcast and has co-founded two medical device companies, held roles at Medicine360, and spent over 12 years at Boston Scientific.
Erica Rogers is a leader at Axena Health, serving on its Board of Directors. She previously spent a decade as President and CEO of Silk Road Medical, guiding the company from early clinical trials through its IPO and eventual acquisition by Boston Scientific. Erica is a returning guest to the podcast and has co-founded two medical device companies, held roles at Medicine360, and spent over 12 years at Boston Scientific.
Ryan Rhodes
Ryan Rhodes is the CEO of EDAP TMS, a company that is innovating prostate cancer treatment through its Focal One robotic high-intensity focused ultrasound system, which eliminates the need for surgery or radiation. With over 30 years of experience in market development, Ryan has dedicated two decades to the field of medical robotics. Prior to his role at EDAP, he served as CEO of Restoration Robotics, where he successfully led the company to a merger with Venus Concept. Ryan also spent more than 13 years at Intuitive Surgical, where he established the global Urology franchise, significantly contributing to the adoption of the da Vinci surgical system. His earlier career includes 11 years at Ethicon (Johnson & Johnson) in various roles encompassing sales, marketing, and market development.
Ryan Rhodes is the CEO of EDAP TMS, a company that is innovating prostate cancer treatment through its Focal One robotic high-intensity focused ultrasound system, which eliminates the need for surgery or radiation. With over 30 years of experience in market development, Ryan has dedicated two decades to the field of medical robotics. Prior to his role at EDAP, he served as CEO of Restoration Robotics, where he successfully led the company to a merger with Venus Concept. Ryan also spent more than 13 years at Intuitive Surgical, where he established the global Urology franchise, significantly contributing to the adoption of the da Vinci surgical system. His earlier career includes 11 years at Ethicon (Johnson & Johnson) in various roles encompassing sales, marketing, and market development.
Kirk Huntsman
Kirk Huntsman is the CEO of Vivos, a company that commercializes a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA). He is a seasoned healthcare entrepreneur with a proven track record of scaling and exiting successful businesses. Kirk founded Dental One, which grew into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling Dental One to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. At Vivos, Kirk and his team are developing proprietary treatments for sleep-related breathing disorders, providing patients with an FDA-cleared alternative to CPAP therapy.
Kirk Huntsman is the CEO of Vivos, a company that commercializes a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA). He is a seasoned healthcare entrepreneur with a proven track record of scaling and exiting successful businesses. Kirk founded Dental One, which grew into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling Dental One to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. At Vivos, Kirk and his team are developing proprietary treatments for sleep-related breathing disorders, providing patients with an FDA-cleared alternative to CPAP therapy.
Topics Discussed
women's health
PCOS
wearable technology
low-frequency electrical stimulation
regulatory pathways
strategic partnerships
direct-to-consumer
retinal imaging
ophthalmology
democratize access
advanced algorithms
automated systems
early signs of disease
diagnostic solution
real-world implementation challenges
Axena Health
pelvic floor therapy
Leva
medtech commercialization
healthcare
medical device
investors
prostate cancer treatment
Focal One
robotic high-intensity focused ultrasound
medical robotics
scalable medtech solution
clinical data
credibility
reimbursement
early adopters
partnerships
Vivos
Kirk Huntsman
obstructive sleep apnea
healthcare entrepreneur
go-to-market strategy
credibility markers
industry partnerships
IPO challenges
YouTube Channel
Podcast has no YouTube channel.
Instagram Profile
Podcast has no Instagram profile.
Episodes
Here's the recent few episodes on Medsider: Learn from Medtech and Healthtech Founders and CEOs.
0:0053:32
Breaking Down Barriers in Women's Health: Interview with Neuraura CEO Claire Dixon
Neuraura is developing LoOop, an over-the-counter wearable that targets PCOS through low-frequency electrical stimulation.
Claire brings over 25 years of international leadership experience to her role as co-founder and CEO of Neuraura. With a master's degree in engineering from Cambridge and an MBA from Harvard, she spent 15 years as a strategic consultant to capital-intensive businesses before transitioning to entrepreneurship. She was recently named among the Top 200 Trailblazing Leaders in Women's Health and femtech by Women of Wearables.
In this interview, Claire shares insights on navigating regulatory pathways, designing for real user needs, and building strategic partnerships to bring innovative women's health solutions to market through a direct-to-consumer approach.
Before we dive into the discussion, I wanted to mention a few things:
First, if youre into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. Youll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If youre interested, go to medsider.com/subscribe to learn more.
Neuraura is developing LoOop, an over-the-counter wearable that targets PCOS through low-frequency electrical stimulation.
Claire brings over 25 years of international leadership experience to her role as co-founder and CEO of Neuraura. With a master's degree in engineering from Cambridge and an MBA from Harvard, she spent 15 years as a strategic consultant to capital-intensive businesses before transitioning to entrepreneurship. She was recently named among the Top 200 Trailblazing Leaders in Women's Health and femtech by Women of Wearables.
In this interview, Claire shares insights on navigating regulatory pathways, designing for real user needs, and building strategic partnerships to bring innovative women's health solutions to market through a direct-to-consumer approach.
Before we dive into the discussion, I wanted to mention a few things:
First, if youre into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. Youll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If youre interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Vicky Demas, CEO of identifeye HEALTH (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.
Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.
In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Vicky Demas, CEO of identifeye HEALTH (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.
Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.
In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Randy Pritchard and Erica Rogers, leaders of Axena Health. Axena is transforming pelvic floor therapy with Leva, a device bringing clinically-proven, supervised pelvic floor muscle training into women’s homes.
Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.
In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Randy Pritchard and Erica Rogers, leaders of Axena Health. Axena is transforming pelvic floor therapy with Leva, a device bringing clinically-proven, supervised pelvic floor muscle training into women’s homes.
Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.
In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Ryan Rhodes, CEO of EDAP TMS. EDAP is changing prostate cancer treatment through Focal One, a robotic high-intensity focused ultrasound (HIFU) system that doesn’t require the use of surgery or radiation.
Ryan has over 30 years of experience in market development, with two decades focused on medical robotics. Before EDAP, Ryan was CEO of Restoration Robotics, where he guided the company to a successful merger with Venus Concept. He spent 13+ years at Intuitive Surgical, establishing the global Urology franchise, which became the company’s entry point for broader adoption of the da Vinci system. He also spent 11 years at Ethicon (J&J) in sales, marketing, and market development.
In this interview,Ryan challenges founders to ask: Are you creating a scalable medtech solution or a product with limited growth potential? He unpacks why standardization and scalability are critical for adoption, how clinical data fuels credibility and reimbursement, and why early adopters take the biggest risks — but also reap the biggest rewards.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Ryan Rhodes, CEO of EDAP TMS. EDAP is changing prostate cancer treatment through Focal One, a robotic high-intensity focused ultrasound (HIFU) system that doesn’t require the use of surgery or radiation.
Ryan has over 30 years of experience in market development, with two decades focused on medical robotics. Before EDAP, Ryan was CEO of Restoration Robotics, where he guided the company to a successful merger with Venus Concept. He spent 13+ years at Intuitive Surgical, establishing the global Urology franchise, which became the company’s entry point for broader adoption of the da Vinci system. He also spent 11 years at Ethicon (J&J) in sales, marketing, and market development.
In this interview,Ryan challenges founders to ask: Are you creating a scalable medtech solution or a product with limited growth potential? He unpacks why standardization and scalability are critical for adoption, how clinical data fuels credibility and reimbursement, and why early adopters take the biggest risks — but also reap the biggest rewards.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Kirk Huntsman, CEO of Vivos, a company commercializing a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA).
Kirk is a seasoned healthcare entrepreneur with a track record for scaling and exiting successful businesses. He founded Dental One, growing it into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling the company to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. Now as CEO of Vivos, Kirk and his team are developing and commercializing proprietary treatments for sleep-related breathing disorders, offering patients an FDA-cleared alternative to CPAP therapy.
In this interview, Kirk talks about his go-to-market strategy, the importance of credibility markers, the complexity of industry partnerships, and the challenges he faced pursuing an IPO.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Kirk Huntsman, CEO of Vivos, a company commercializing a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA).
Kirk is a seasoned healthcare entrepreneur with a track record for scaling and exiting successful businesses. He founded Dental One, growing it into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling the company to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. Now as CEO of Vivos, Kirk and his team are developing and commercializing proprietary treatments for sleep-related breathing disorders, offering patients an FDA-cleared alternative to CPAP therapy.
In this interview, Kirk talks about his go-to-market strategy, the importance of credibility markers, the complexity of industry partnerships, and the challenges he faced pursuing an IPO.
Before we dive into the discussion, I wanted to mention a few things:
First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.
Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!
We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!
In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.
